Package | us.nlm.vsac |
Type | ValueSet |
Id | 2.16.840.1.113762.1.4.1078.936 |
FHIR Version | R4 |
Source | http://fhir.org/packages/us.nlm.vsac/https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1078.936/expansion |
URL | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.936 |
Version | 20240711 |
Status | active |
Date | 2024-07-11T01:03:01-04:00 |
Name | T2DMMedsBenefittingHFWithEGFR20MLMin |
Title | T2DM meds benefitting HF with eGFR >= 20 mL/min |
Realm | us |
Authority | hl7 |
Purpose | (Clinical Focus: T2DM meds benefitting HF, as per ADA 2024 Standards of Care, with eGFR >= 20 ml/min),(Data Element Scope: RxCUIs for medications containing canagliflozin, dapagliflozin, empagliflozin, or ertugliflozin),(Inclusion Criteria: Valid RxCUIs),(Exclusion Criteria: Invalidated RxCUIs) |
No resources found
CodeSystem | |
rxnorm | RxNorm |
rxnorm | RxNorm |
ValueSet | |
2.16.840.1.113762.1.4.1078.926 | Canagliflozin meds |
2.16.840.1.113762.1.4.1078.927 | Empagliflozin meds |
2.16.840.1.113762.1.4.1078.928 | Dapagliflozin meds |
2.16.840.1.113762.1.4.1078.929 | Ertugliflozin meds |
No narrative content found in resource